Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    Special Populations
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    March 10, 2023
    How I Practice Mindfulness as an Oncology Nurse
    Nurse well-being
    How I Practice Mindfulness as an Oncology Nurse
    March 03, 2023
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    Clinical Full-Body Skin Examination Identifies Twice the Number of Cancers
    Melanoma

    Clinical Full-Body Skin Examination Identifies Twice the Number of Cancers

    A dermatologist-performed total-body skin examination (TBSE) identifies more than two times the number of skin cancers than patients or other providers discovered, researchers reported in the International Journal of Women’s Dermatology. The cancers may otherwise have gone undiagnosed, leading to later-stage disease and poorer outcomes.

    November 03, 2021
    Bringing Biosignatures to the Bedside
    Targeted therapy

    Bringing Biosignatures to the Bedside

    With the growth of genomics and targeted therapy, nurse scientists are gaining deeper understanding the vast facets of patients’ symptom experience, and biosignatures could be the key to unlocking the next frontier in symptom science research.

    November 02, 2021
    Many Popular Online Cancer Articles Contain Misleading Information, NCI Says
    Patient Education

    Many Popular Online Cancer Articles Contain Misleading Information, NCI Says

    With a plethora of information available online, patients with cancer and their families have access to plenty of resources to learn more about their diagnosis and treatment options. However, one-third of the online articles about cancer circulating on social media contain incorrect information, according to findings from a 2021 study published in the Journal of the National Cancer Institute.

    October 29, 2021
    Find Solace in Silence
    Nurse well-being

    Find Solace in Silence

    A balanced life allows us to function at our best. Our bodies do that naturally through homeostasis, a familiar term from nursing school, by self-regulating physiological processes to ensure equilibrium and optimal functioning. But our brains sometimes need help to self-regulate, and one way to do that is to practice silence. After a day of noise and action, silence and solitude can calm and restore you.

    October 28, 2021
    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf

    A first-of-its-kind antibody-drug conjugate for multiple myeloma, belantamab mafodotin-blmf (Blenrep) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2020. The approval was based on clinical trial findings that demonstrated a 31% overall response rate that lasted at least six months in 73% of responders.

    October 26, 2021
    What Is a Liquid Biopsy?
    Clinical practice

    What Is a Liquid Biopsy?

    All cells (healthy cells and tumor cells) in the body shed DNA, called cell-free DNA (cfDNA). When it’s only from tumor cells, it’s referred to as circulating tumor DNA (ctDNA), although cfDNA and ctDNA are sometimes used interchangeably.

    October 25, 2021
    The Case of the Missing Oral Mucositis
    Radiation therapy

    The Case of the Missing Oral Mucositis

    Bob is a 68-year-old patient with early-stage cancer of the glottic larynx (right true vocal cord). He is receiving a hypofractionated three-dimensional conformal therapy without concurrent chemotherapy, 225 cGy each day for five days a week to a total dose of 6,075 cGy. He is now in his fourth week of treatment at 4,000 cGy and experiencing side effects. His voice is a high-pitched whisper and talking requires a lot of effort. He reports pain when swallowing his favorite foods like nachos and has lost 2 kg since his last weight check four days ago. Bob also reports some dizziness with position changes, and his pulse and blood pressure screenings show that he’s mildly orthostatic.

    October 22, 2021
    FDA Amends EUAs With Booster Doses for COVID-19 Vaccines
    COVID-19

    FDA Amends EUAs With Booster Doses for COVID-19 Vaccines

    On October 20, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) for the Moderna and Janssen (Johnson and Johnson) COVID-19 vaccines to allow for the use of a single booster dose for certain populations.

    October 22, 2021
    New Study Supports CRC Screening for People Older Than 75
    Cancer screening

    New Study Supports CRC Screening for People Older Than 75

    Colorectal cancer (CRC) screening may be beneficial for certain patients aged 75–85, according to findings from a new study. The researchers reported the results in JAMA Oncology.

    October 20, 2021
    The Case of the End-of-Life Evaluation
    End of life (EOL)

    The Case of the End-of-Life Evaluation

    Ron, your 73-year-old patient, decides to transition to hospice care after receiving lung cancer treatment for three years. His partner finds Ron’s decision to move to hospice difficult to accept and encourages him to look for a clinical trial or try alternative treatments. You suggest that the couple speaks with a hospital chaplain, and Ron agrees. His surprised partner says, “Why do you want to talk with a chaplain? We’ve never been religious!”

    October 19, 2021
    Genetic Disorder Reference Sheet: ATM Pathogenic Variants
    Genetics & genomics

    Genetic Disorder Reference Sheet: ATM Pathogenic Variants

    An estimated 1%–2% of adults have one pathogenic ataxia telangiectasia mutated (ATM) gene variant (heterozygous) and are considered carriers. People who are homozygous (two altered copies) have ataxia-telangiectasia (A-T), a hereditary condition that often appears in childhood and is characterized by progressive neurologic problems that lead to difficulty walking and an increased risk for developing various malignancies. Children with A-T may begin staggering and appear unsteady (ataxia) shortly after learning to walk.

    October 18, 2021
    FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

    On October 15, 2021, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II–IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 1% of tumor cells as determined by an FDA-approved test. 

    October 15, 2021
    NIH Provides $185 Million to Advance Understanding of Human Genome Functions
    Cancer research

    NIH Provides $185 Million to Advance Understanding of Human Genome Functions

    To drive the advancement of our understanding of the human genome, the National Institute of Health (NIH) is providing $185 million in funding over the next five years, the agency announced in September 2021.

    October 15, 2021
    Interprofessional Collaboration Helps Improve Cancer Care
    Advanced Practice Nursing (APRN)

    Interprofessional Collaboration Helps Improve Cancer Care

    Much of the care we provide is complex and requires the contributions of many knowledgeable and experienced professionals. To satisfy the National Academy of Medicine recommendations of providing safe, timely, effective, efficient, equitable, and patient-centered care, healthcare professionals must function as highly collaborative teams.

    October 14, 2021
    FDA Reports Worldwide Recall of Lidocaine HCl Topical Solution 4% Because of Super Potency
    U.S. Food and Drug Administration (FDA)

    FDA Reports Worldwide Recall of Lidocaine HCl Topical Solution 4% Because of Super Potency

    On October 13, 2021, the U.S. Food and Drug Administration (FDA) reported Teligent Pharma’s voluntary recall of five lots of lidocaine HCl topical solution 4% in a 50 ml screw cap glass bottle to the user level because the firm’s testing found it to be super potent based on an out-of-specification result obtained at the 18-month stability timepoint.

    October 14, 2021
    Legislators Call for Improvement in Palliative Care and Hospice Workforce
    Hospice

    Legislators Call for Improvement in Palliative Care and Hospice Workforce

    Legislators across the United States are recognizing what ONS has advocated for more than a decade: the need for improved access to and better understanding of palliative and hospice care. In September 2021, Senator Tammy Baldwin (D-WI) and Representative Yvette D. Clarke (D-NY) voiced their support for palliative care through a letter to the U.S. Congress.

    October 13, 2021
    FDA Approves Pembrolizumab Combination for First-Line Treatment of Cervical Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab Combination for First-Line Treatment of Cervical Cancer

    On October 13, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. 

    October 13, 2021
    FDA Approves Abemaciclib With Endocrine Therapy for Early Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Abemaciclib With Endocrine Therapy for Early Breast Cancer

    On October 12, 2021, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio®) with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk for recurrence and a Ki-67 score ≥ 20%, as determined by an FDA-approved test. This is the first CDK4/6 inhibitor approved for adjuvant treatment of breast cancer.  

    October 13, 2021
    HER2 Therapies May Be Effective in a Variety of Solid Tumors
    Research

    HER2 Therapies May Be Effective in a Variety of Solid Tumors

    Researchers have found that 2%–3% of all solid tumors overexpress or amplify HER2 protein that may be a target for drugs such as pertuzumab and trastuzumab, particularly in KRAS-variant disease. They presented their findings during the 2021 American Society of Clinical Oncology annual meeting.

    October 13, 2021
    Evidence-Based Practice Gives Oncology Nurses Knowledge and Standards for Clinical Care
    Nursing evidence-based practice

    Evidence-Based Practice Gives Oncology Nurses Knowledge and Standards for Clinical Care

    We have an approximately 14- to 17-year gap between the inception of research discovery and the implementation of findings into clinical practice. As a profession, nurses have a shared responsibility to address the challenge of identifying and overcoming barriers to evidence-based practice (EBP) implementation to provide the best possible clinical care for patients. My primary area of focus as a researcher is on using EBP to improve patient, staff, and organizational outcomes through the Science and Practice Aligned Within Nursing (SPAWN) model, a framework for applying EBP to clinical nursing care.

    October 12, 2021
    It Takes a Team to Confront Moral Distress
    Compassion fatigue

    It Takes a Team to Confront Moral Distress

    Unbearable levels of stress, burnout, frustration, disappointment, and even fear are plaguing today’s healthcare providers more than ever before. But for oncology nurses, moral distress and compassion fatigue have always been in the background when caring for patients with a serious illness.

    October 12, 2021
    Nursing Considerations for Bladder Cancer Survivorship Care
    Survivorship care plans

    Nursing Considerations for Bladder Cancer Survivorship Care

    Bladder cancer is the sixth most common cancer in the United States, with an estimated 83,730 adult diagnoses in 2021. Smoking is the greatest risk factor (47% of all cases occur in smokers), followed by advancing age and sex (assigned males are four times more likely to develop bladder cancer than those assigned female). The incidence rate in White people is double that of Black people, but Black people are twice as likely to die from the disease.

    October 07, 2021
    Radioprotectant May Also Be a Radiobooster
    Radiation therapy

    Radioprotectant May Also Be a Radiobooster

    Initially studied for its radioprotective effects on healthy cells, avasopasem may also increase cancer cells’ response to radiation treatment, researchers reported in Science Translational Medicine.

    October 06, 2021
    PhD and DNP Students Collaborate to Implement Practice-Driven Research
    Nursing evidence-based practice

    PhD and DNP Students Collaborate to Implement Practice-Driven Research

    Evidence-based practice is dual sided: nurse scientists conduct research, and clinical nurses implement those findings into practice. Working together, they improve care by developing cancer survivorship programs, reducing cancer risk, and assessing cancer care in vulnerable populations. The University of Washington School of Nursing’s (UW SoN’s) partnership with Confluence Health, one of the largest healthcare providers in north central Washington, built a novel program to identify gaps in research and implementation and elicit projects that influence healthcare outcomes.

    October 05, 2021
    Practice Change: Transform Cancer Care Through Quality Improvement and Evidence-Based Practice
    Nursing evidence-based practice

    Practice Change: Transform Cancer Care Through Quality Improvement and Evidence-Based Practice

    Most nurses have not received formal training in quality improvement (QI) methodology, and many workplaces lack the resources to efficiently implement evidence-based practice (EBP), which results in delays in translating science into practice. But ONS members are overcoming those barriers and leading the way in effectively developing, implementing, and sustaining practice changes.

    October 05, 2021
    FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

    On October 1, 2021, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus™) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    October 04, 2021
    FDA Issues Marketing Denial Orders for 55,000 Flavored E-Cigarette Products
    U.S. Food and Drug Administration (FDA)

    FDA Issues Marketing Denial Orders for 55,000 Flavored E-Cigarette Products

    In August 2021, the U.S. Food and Drug Administration (FDA) denied about 55,000 flavored e-cigarette products’ marketing applications for failing to provide evidence that they appropriately protect public health.

    October 01, 2021
    Can Compassion Bust Burnout and Restore Resilience?
    Nurse well-being

    Can Compassion Bust Burnout and Restore Resilience?

    Stress is a normal and necessary part of life. However, prolonged emotional tension takes stress to a new level for many people, including oncology nurses. But what is the antidote to cumulative pressure? The evidence for compassion’s benefits during stress is compelling.

    September 30, 2021
    Proton Pump Inhibitors May Boost Radiation’s Effects
    Radiation therapy

    Proton Pump Inhibitors May Boost Radiation’s Effects

    September 29, 2021
    State Cancer Registries Studies Find Nearly All Patients With Cancer Recovered From COVID-19
    COVID-19

    State Cancer Registries Studies Find Nearly All Patients With Cancer Recovered From COVID-19

    Many patients are delaying their recommended cancer screenings because of fear of death from COVID-19 coronavirus infection, according to the Centers for Disease Control and Prevention (CDC). However, those fears may not align with real-world outcomes, the agency said, when it reported July 2021 study findings from Arkansas and North Carolina.

    September 28, 2021
    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy

    Initially marketed in April 2020 for treatment of adults with metastatic triple negative breast cancer, sacituzumab govitecan-hziy (Trodelvy®) received an additional approval in 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer with prior treatments.

    September 28, 2021
    IntegraDose Compounding Services Issues Voluntary Nationwide Recall of Cefazolin Injection Products Because of a Lack of Sterility Assurance
    U.S. Food and Drug Administration (FDA)

    IntegraDose Compounding Services Issues Voluntary Nationwide Recall of Cefazolin Injection Products Because of a Lack of Sterility Assurance

    On September 21, 2021, the U.S. Food and Drug Administration (FDA) reported IntegraDose Compounding Services’ voluntary recall of nine lots of cefazolin 2 g in 20 ml syringe for injection and two lots of cefazolin 3 g in 100 ml 0.9% sodium chloride bag for injection because of a lack of sterility assurance resulting from compounding in a newly installed biologic safety cabinet without completing dynamic smoke study testing.

    September 27, 2021
    What the Evidence Says for Traditional Chinese Medicine Ma Zi Ren Wan for Constipation
    Complementary therapy

    What the Evidence Says About Traditional Chinese Medicine Ma Zi Ren Wan for Constipation

    A common and distressing symptom among patients with a variety of health diagnoses as well as the general population, constipation is characterized by reduced stool frequency, incomplete evacuation, straining, and a sense of anorectal blockage. Nearly 43%–58% of patients with cancer report constipation caused by a variety of factors, including organic, functional, or drug associated. Standard treatment options such as fiber supplements, laxatives, and stool softeners are not entirely effective and can cause adverse effects.

    September 24, 2021
    FDA Approves Ruxolitinib for Chronic Graft-Versus-Host Disease
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ruxolitinib for Chronic Graft-Versus-Host Disease

    On September 22, 2021, the U.S. Food and Drug Administration (FDA) approved ruxolitinib (Jakafi®) for chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.

    September 23, 2021
    FDA Approves Cabozantinib for Differentiated Thyroid Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Cabozantinib for Differentiated Thyroid Cancer

    On September 17, 2021, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx®) for adult and pediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor (VEGFR)-targeted therapy and who are ineligible for or refractory to radioactive iodine treatment.

    September 22, 2021
    FDA Grants Accelerated Approval to Tisotumab Vedotin-Tftv for Recurrent or Metastatic Cervical Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tisotumab Vedotin-Tftv for Recurrent or Metastatic Cervical Cancer

    On September 20, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak™), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.

    September 21, 2021
    The Case of the Triple-Negative Breast Cancer Targeted Treatment
    Breast cancer

    The Case of the Triple-Negative Breast Cancer Targeted Treatment

    Ophelia is a 42-year-old patient who has been diagnosed with triple-negative breast cancer (TNBC). She completed neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel and carboplatin. Her postsurgical pathology shows residual disease in the tumor (3.5 cm down from 4 cm) and 12 out of 18 lymph nodes that are positive for cancer. Ophelia tells you that she is very discouraged and expected a better treatment outcome.

    September 21, 2021
    Pfizer Expands Recall to Include All Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content
    U.S. Food and Drug Administration (FDA)

    Pfizer Expands Recall to Include All Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

    On September 17, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of all lots of varenicline 0.5 mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, at or above the FDA interim acceptable intake limit. FDA said that while Pfizer is undertaking the precautionary measure, alternative suppliers have been approved in the United States.

    September 20, 2021
    ONS Bridge

    Understanding the Endocrine System Helps Nurses Be Vigilant in Watching for Common Symptoms

    A basic understanding of the endocrine system is helpful in assessing and monitoring patients for common side effects of cancer and its treatments, Marianne Davies, DNP, ACNP, FAAN, from Yale Comprehensive Cancer Center, said during a session held at the ONS BridgeTM virtual conference on September 16, 2021. She provided attendees with a complete overview and associated disorders, emphasizing the need for nurses to be vigilant in watching for signs and symptoms in their patients.

    September 16, 2021
    ONS Bridge

    Best Practices to Manage Electrolytes in Patients With Hypomagnesemia or Hypokalemia

    Patients with cancer may experience low levels of magnesium and potassium for a variety of reasons throughout the course of their treatment, and both conditions can be serious or even fatal. Oncology nurses are critical in educating patients and understanding the benefits and potential concerns associated with electrolyte replacement, Puja Patel, PharmD, BCOP, from Northwestern Medicine Delnor Cancer Center in Geneva, IL, said during a session during the ONS BridgeTM virtual conference on September 16, 2021.

    September 16, 2021
    ONS Bridge

    Nurses Humanize and Normalize Digital Health as Technology Becomes Part of the Care Team

    COVID-19 forced healthcare providers to pivot to digital health, but an estimated 70% of patients still deferred or canceled their care, including routine cancer screening. Technology is an essential tool in cancer care, according to Abigail Baldwin-Medsker, MSN, RN, OCN®, of Memorial Sloan Kettering Cancer Center, who presented a session at the ONS BridgeTM virtual conference on September 16, 2021.

    September 16, 2021
    FDA Grants Accelerated Approval to Mobocertinib for Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Variants
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Mobocertinib for Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Variants

    On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity™) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion variants, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

    September 16, 2021
    Nursing Considerations for Thyroid Cancer Survivorship Care
    Survivorship care plans

    Nursing Considerations for Thyroid Cancer Survivorship Care

    In 2021, approximately 44,000 people will be diagnosed with thyroid cancer, most commonly younger patients and assigned females at birth.

    September 16, 2021
    ONS Bridge

    New Multiple Myeloma Treatments Present New Challenges in Side Effect Management

    New strategies are emerging to manage the complex side effects and adverse events from multiple myeloma (MM) therapies, Lorraine Mack, APN/MSN CNL, OCN®, AOCNS®, and Dodi Georges, MSN, CWON, OCN®, both from Northwestern Medicine, said during a session held September 14, 2021, at the ONS BridgeTM virtual conference. They shared best practices for nursing interventions for patients undergoing new treatment options.

    September 14, 2021
    ONS Bridge

    Don’t Delay When Managing irAEs From Immune Checkpoint Inhibitors

    To prevent life-threatening complications that could affect treatment adherence and outcomes, oncology nurses must be vigilant in early recognition and treatment of immune-related adverse events (irAEs), Lisa A. Kottschade, MSN, APRN, CNP, from Mayo Clinic in Rochester, MN, said during a session held at the ONS BridgeTM virtual conference on September 14, 2021. She provided an overview of what to watch for and nursing considerations for common irAEs.

    September 14, 2021
    Patient-Advocacy-Provider Partnerships and Networks Support Rare Cancer Research
    Cancer research

    Patient-Advocacy-Provider Partnerships and Networks Support Rare Cancer Research

    My area of research focus is adults with primary central nervous system (CNS) tumors, which represent less than 2% of all diagnosed cancers. Because of the cancers’ rarity, access to diagnosed patients for research initiatives is limited. My team’s program, NCI-CONNECT, a part of the Rare Tumor Patient Engagement Network supported by the Cancer Moonshot, is advancing our understanding of adults with rare CNS cancers by establishing patient-advocacy-provider partnerships and networks to improve care and treatment approaches.

    September 14, 2021
    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities
    Cancer research

    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities

    When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.

    September 14, 2021
    ONS Bridge

    How One Organization Developed Tools to Predict Opioid Use Disorder Among Patients

    Opioids are one strategy to help manage the cancer-related pain that nearly 75% of patients with cancer experience throughout the disease or its treatment. However, the prevalence of opioid misuse disorder (OUD) among patients with cancer is believed to be at least equal to that of the general population, Debra Rodrigue, MA, RN-BC, AOCNS®, explained during a session for the ONS BridgeTM virtual conference on September 9, 2021.

    September 09, 2021
    ONS Bridge

    Bridge Educational Gaps by Maximizing the Effectiveness of Your Virtual Programs

    From elementary to college environments, virtual education is now commonplace, and, according to Jillian A. Russell, MSN, RN, NPD-BC, program manager at the Association for Nursing Professional Development, careful planning and creativity can make remote experiences just as—or even more—effective as traditional, in-person learning.

    September 09, 2021
    Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes
    Research

    Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes

    TP53 and MYOD1 variants are associated with more aggressive forms of rhabdomyosarcoma, a rare childhood cancer, and poorer outcomes, according to the results of the largest international genomic profiling study of the disease. The findings, which were published in the Journal of Clinical Oncology, have implications for somatic biomarker testing to guide tailored treatment approaches.

    September 09, 2021
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Page 4
    • Current page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲